



Dihydroartemisinin-Piperaquine Dose Impact Study Group Acknowledgements

WWARN thanks the following investigators who contributed individual patient data from published or unpublished clinical studies to the DHA-PQP Dose Impact Study Group pooled analysis investigating:

- the mg/kg dosing range of the clinically-adopted ACT partner drug piperaquine; and
- the effects of piperaquine mg/kg dosing on clinical outcome.

1. Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM. Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated *Plasmodium falciparum* malaria in central Sudan. *Annals of Tropical Medicine and Parasitology* 2010;104(4):319-26.
2. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. *Clinical Infectious Disease*, 2009;49(11):1629-37.
3. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. *Journal Infectious Disease* 2004;190(10):1773-82.
4. Awab GR and Woodrow C. A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan 2007.
5. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. *PLoS One* 2009;4(11):e7871.
6. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan coast. *PLoS One* 2011;6(11):e26005.
7. Gaye O. Study on the efficacy of antimalarial drugs in the suburbs of Dakar in collaboration with the NMCP and the WHO, 2010.
8. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, et al. A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. *PLoS One* 2007 Oct 31;2(10):e1101
9. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and post-treatment prophylaxis against multidrug-resistant *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Clinical Infectious Disease* 2007;44(8):1067-74.
10. Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. *Tropical Medicine and International Health* 2007 Feb;12(2):251-9
11. Kanya MR, Yeka A, Bukirwa H, Lugeswa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. *PLoS Clinical Trials* 2007;2(5):e20.
12. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D and D'Alessandro U. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated *Plasmodium falciparum* malaria in Rwandan children. *Transactions of the Royal Society of Tropical Medicine* 2006 Dec;100(12):1105-11

13. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorra PS, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. *New England Journal Medicine* 2008;359(24):2545-57.
14. Mayxay M, Keomany S, Khanthavong M, Souvannasing P, Stepniewska K, Khomthilath T, et al. A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos. *American Journal of Tropical Medicine Hygiene* 2010;83(6):1221-9.
15. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, Keola S, et al. An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). *Tropical Medicine and International Health* 2006;11(8):1157-65.
16. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. *Malaria Journal* 2008 Nov 18;7:237
17. Nguyen TN and Tran HT. Clinical investigation of in-vivo susceptibility of P.falciparum to artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam, 2010.
18. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihah F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. *Lancet* 2007;369(9563):757-65.
19. Sawa P, Shekalaghe S, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial, 2012.
20. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. *Lancet* 2006;367(9528):2075-85.
21. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. *Lancet Infectious Diseases* 2010;10(10):673-81.
22. The 4ABC Study Group, A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. *PLoS Medicine* 2011;8(11):e1001119.
23. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. *PLoS One* 2010;5(7):e11880.
24. Yavo W, Faye B, Kuete T, Djohan V, Oga SA, Kassi RR, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. *Malaria Journal* 2011;10:198.
25. Yeka A, Dorsey G, Kanya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. *PLoS One* 2008;3(6):e2390.
26. Yeka A, Tibenderana J, Achan J, D'Alessandro U and Talisuna AO. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. *PLoS One* 2013;8(1):e53772
27. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. *Clinical Infectious Diseases* 2007;45(11):1453-61.